Pacira BioSciences (PCRX) News Today $19.75 -0.08 (-0.40%) (As of 10:26 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Wellington Management Group LLP Sells 32,486 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Wellington Management Group LLP lowered its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 6.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 454,649 shares of the company's stock after sellDecember 17 at 3:43 AM | marketbeat.comFmr LLC Cuts Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Fmr LLC decreased its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 97.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 67,165 shares of the company's stock after selDecember 17 at 3:09 AM | marketbeat.comEquities Analysts Offer Predictions for PCRX FY2024 EarningsDecember 17 at 1:33 AM | americanbankingnews.comShareholder Rights Advocates at Levi & Korsinsky Investigate Pacira BioSciences, Inc. (PCRX) Regarding Possible Securities Fraud ViolationsDecember 16 at 8:45 AM | markets.businessinsider.comJanus Henderson Group PLC Cuts Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)Janus Henderson Group PLC reduced its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 96.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,319 shares of the company's stoDecember 16 at 3:40 AM | marketbeat.comFY2024 EPS Forecast for Pacira BioSciences Raised by AnalystPacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Stock analysts at Zacks Research boosted their FY2024 EPS estimates for shares of Pacira BioSciences in a note issued to investors on Wednesday, December 11th. Zacks Research analyst R. Department now expects that the company will earn $2.60December 16 at 1:08 AM | marketbeat.comQ1 EPS Forecast for Pacira BioSciences Lowered by AnalystDecember 15 at 1:07 AM | americanbankingnews.comQ1 EPS Estimate for Pacira BioSciences Lowered by AnalystPacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Analysts at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for Pacira BioSciences in a research note issued on Wednesday, December 11th. Zacks Research analyst R. Department now forecasts that the company will earn $0.60December 13, 2024 | marketbeat.comVerition Fund Management LLC Makes New $493,000 Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)Verition Fund Management LLC purchased a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 32,788 shares of the company's stock, valued at approxDecember 12, 2024 | marketbeat.comDOMA Perpetual Capital to nominate four candidates to Pacira’s boardDecember 12, 2024 | markets.businessinsider.comDOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.December 11, 2024 | prnewswire.comCentiva Capital LP Acquires Shares of 26,473 Pacira BioSciences, Inc. (NASDAQ:PCRX)Centiva Capital LP acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 26,473 shares of the company's stock, valued at approximatelyDecember 10, 2024 | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)December 6, 2024 | globenewswire.comDecoding 6 Analyst Evaluations For Pacira BioSciencesDecember 4, 2024 | benzinga.comBNP Paribas Financial Markets Increases Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)BNP Paribas Financial Markets increased its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 269.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 395,695 shares of the company's stock aftDecember 4, 2024 | marketbeat.comPacira Awarded New U.S. Patent Covering EXPAREL CompositionDecember 3, 2024 | globenewswire.comQ4 EPS Forecast for Pacira BioSciences Reduced by AnalystPacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Equities researchers at Zacks Research dropped their Q4 2024 earnings per share (EPS) estimates for shares of Pacira BioSciences in a research report issued to clients and investors on Wednesday, November 27th. Zacks Research analyst R. DeparDecember 2, 2024 | marketbeat.comAlgert Global LLC Takes Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Algert Global LLC bought a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 58,848 shares of the company's stock, valued at approximately $8November 30, 2024 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from AnalystsPacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has been assigned an average rating of "Hold" from the ten research firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, four have issued a hold raNovember 30, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Takes $1.21 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 80,533 shares ofNovember 27, 2024 | marketbeat.comPacira BioSciences: Not Done Yet Despite Devastating Share Price LossesNovember 25, 2024 | seekingalpha.comSegall Bryant & Hamill LLC Takes Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Segall Bryant & Hamill LLC acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 32,061 shares of the company's stock, valued aNovember 25, 2024 | marketbeat.comVictory Capital Management Inc. Boosts Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Victory Capital Management Inc. increased its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 39.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,228 shares of the company's stock after buyingNovember 25, 2024 | marketbeat.comPacer Advisors Inc. Acquires 2,799,434 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Pacer Advisors Inc. grew its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 129.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,962,221 shares of the company's stock after buying an aNovember 22, 2024 | marketbeat.comPacira BioSciences Inc PCRXNovember 21, 2024 | morningstar.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Global Alpha Capital Management Ltd.Global Alpha Capital Management Ltd. lowered its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 56.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,740 shares of the company's stock afterNovember 20, 2024 | marketbeat.comEmpowered Funds LLC Makes New $3.29 Million Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)Empowered Funds LLC bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 218,336 shares of the company's stock, valued at approximately $3,286,000. EmpNovember 19, 2024 | marketbeat.comJanney Montgomery Scott LLC Takes Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Janney Montgomery Scott LLC purchased a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 52,708 shares of the company's stock,November 18, 2024 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Impax Asset Management Group plcImpax Asset Management Group plc grew its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 81.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 470,603 shares of the company's stock after purchasing anNovember 16, 2024 | marketbeat.comPacira announces 104-week safety, efficay data for PCRX-201November 15, 2024 | markets.businessinsider.comPacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the KneeNovember 14, 2024 | globenewswire.comLos Angeles Capital Management LLC Has $2.20 Million Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)Los Angeles Capital Management LLC increased its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 942.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 145,930November 14, 2024 | marketbeat.comPacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare ConferencesNovember 12, 2024 | finance.yahoo.comBarclays Issues Pessimistic Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock PriceBarclays reduced their target price on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating on the stock in a research report on Tuesday.November 12, 2024 | marketbeat.comRobeco Institutional Asset Management B.V. Invests $1.05 Million in Pacira BioSciences, Inc. (NASDAQ:PCRX)Robeco Institutional Asset Management B.V. bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 69,944 shares of the company's stock, valued at approximately $1,053,000.November 11, 2024 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | insidermonkey.comPacira BioSciences' (PCRX) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $22.00 target price on shares of Pacira BioSciences in a research note on Friday.November 8, 2024 | marketbeat.comEvaluating Pacira BioSciences: Insights From 8 Financial AnalystsNovember 8, 2024 | benzinga.comPositive Outlook for Pacira Pharmaceuticals Despite Mixed Q3 2024 Results, Driven by Exparel’s Strong Market Position and Strategic InitiativesNovember 8, 2024 | markets.businessinsider.comRoyal Bank of Canada Issues Positive Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock PriceRoyal Bank of Canada lifted their target price on shares of Pacira BioSciences from $15.00 to $16.00 and gave the company a "sector perform" rating in a research note on Thursday.November 7, 2024 | marketbeat.comPacira Pharmaceuticals Faces Q3 Loss Amid Revenue GrowthNovember 7, 2024 | markets.businessinsider.comPacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ...November 7, 2024 | finance.yahoo.comPacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comPacira BioSciences Reports Third Quarter 2024 Financial ResultsNovember 6, 2024 | globenewswire.comImpax Asset Management Group plc Has $7.08 Million Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)Impax Asset Management Group plc lifted its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 81.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 470,603 shares of the company'sNovember 6, 2024 | marketbeat.comCenters for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient SettingsNovember 5, 2024 | finance.yahoo.comPacira announces CMS established additional payment for iovera in outpatientNovember 5, 2024 | markets.businessinsider.comInsights into Pacira BioSciences's Upcoming EarningsNovember 5, 2024 | benzinga.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Rice Hall James & Associates LLCRice Hall James & Associates LLC trimmed its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 73.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 268,337 shares of the company's stock after selling 730,288 shares durNovember 1, 2024 | marketbeat.comPacira BioSciences (PCRX) Scheduled to Post Quarterly Earnings on WednesdayPacira BioSciences (NASDAQ:PCRX) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.com Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Could this be the hottest crypto discovery of all time? (Ad)I want to let you in on what may be the hottest crypto discovery of all time… One that has NOTHING to do with creating a crypto wallet or touching ANY risky coin for that matter. Instead, it’s a way that could let regular folks like you and me target 10X the possible results you’d expect from buying Bitcoin … in just a fraction of the time It sounds nuts… trust me I know that… But just as I would hate for you to jump into any risky crypto asset… That’s exactly how I would hate for you to miss out on what could be a safer and better way to benefit from the crypto bull run of 2024. Which is why I’m giving you an opportunity to get all the details of this iconic crypto discovery with you for the first time ever… completely free… If you want in, Just Click Here PCRX Media Mentions By Week PCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCRX News Sentiment▼0.380.65▲Average Medical News Sentiment PCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCRX Articles This Week▼185▲PCRX Articles Average Week Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Perrigo News Today Supernus Pharmaceuticals News Today Omeros News Today Nektar Therapeutics News Today Assembly Biosciences News Today Cumberland Pharmaceuticals News Today Eli Lilly and Company News Today Johnson & Johnson News Today AbbVie News Today Merck & Co., Inc. News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCRX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
